Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501046 · ClinicalTrials.gov registry record · Phase 3
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)
A Phase 3 study, sponsored by Tanabe Pharma Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,015
- Enrollment target
NCT00501046 is a Phase 3 study that has completed, run by Tanabe Pharma Corporation. The registered enrollment target is 1,015 participants.
The verdict
NCT00501046, a Phase 3 study, has completed, sponsored by Tanabe Pharma Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,015 participants
- Enrollment target
Study Summary
1\) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite outcome of initiation of dialysis, kidney transplant or doubling of serum creatinine (sCr) when compared with placebo; 2) To evaluate the safety and tolerability of long-term AST-120 therapy in patients with CKD; 3) To evaluate the effects of AST-120 versus placebo, on other measures of renal function and quality of life.
Interventions
- DRUG Placebo
- DRUG AST-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,015 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501046
The ClinicalTrials.gov registry entry for NCT00501046 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,015 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00501046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00501046 about?
NCT00501046 is a clinical study titled "A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)". 1\) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite outcome of initiation of dialysis, kidney transplant or doubling of serum c...
What is the current status of trial NCT00501046?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,015 participants. The study started on 2007-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00501046?
The interventions under investigation include: Placebo (DRUG), AST-120 (DRUG).
Who is sponsoring clinical trial NCT00501046?
This trial is sponsored by Tanabe Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.